Fight For Sight, PBA announce new public health award
January 2nd 2013Fight for Sight and Prevent Blindness America (BPA) will co-sponsor a new annual public health research fellowship. The award, entitled “Fight for Sight-Prevent Blindness America Public Health Award,” is a one-time, $20,000 grant for 1 year of full-time research on improving eye health and safety.
CXL a promising adjunct for hyperopic LASIK
December 26th 2012Initial findings based on 2 years of follow-up in a randomized, fellow-eye controlled study indicate that adding cornea collagen crosslinking (CXL) routinely to LASIK for treatment of hyperopia or hyperopic astigmatism is safe and may stabilize the refractive outcome better compared with LASIK alone, according to Jonathan B. Kahn, MD.
Companies seek EU approval for Eylea to treat ME after CRVO
December 26th 2012Regeneron Pharmaceuticals Inc. and Bayer HealthCare reported that Bayer HealthCare has submitted an application for marketing authorization in Europe for Eylea (aflibercept) injection for the treatment of macular edema (ME) following central retinal vein occlusion (CRVO).
Larger graft available for damaged ocular surfaces
December 19th 2012A new, larger designed size of AmnioGraft biologic ocular transplantation graft, AmnioGraft AG-5050 (Bio-Tissue Inc.), is now available for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. The graft consists of amniotic membrane to protect, repair, and heal damaged eye surfaces.
Implant not recommended in UK, but to be launched in European market
December 12th 2012The fluocinolone acetonide intravitreal implant (Iluvien, Alimera) has not met the UK’s cost-effectiveness thresholds for treating DME. Alimera has, however, signed an agreement with Quintiles for the implant’s European launch.